ZNF318

Across TCGA pan-cancer cohorts, ZNF318 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated ZNF318 data layer compared with 24 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in small cell lung cancer (SCLC), where higher ZNF318 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ZNF318 expression acts as an unfavorable survival marker, although some lineages such as SKCM show a favorable association.

SCLC, KICH, and SKCM are the cancer types where ZNF318 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SCLC	OS	Median	All	0.288	0.711	.010	15	view →
KICH	DFS	Median	All	0.102	0.848	.004	13	view →
SKCM	DFS	Median	II,III,IV	0.941	0.658	.003	10	view →
SARC	DFS	Median	All	0.095	0.632	.002	6	view →
LUAD	OS	Median	II,III,IV	0.307	0.748	.046	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

ZNF318–SCLC (OS)

Open the SCLC breakdown →